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Introduction
Disruption of aortic homeostasis arising from genetic defects or 
exposure to environmental risk factors leads to localized abnormal 
widening of the aorta, a degenerative disease state termed aortic 
aneurysm that can affect the length of the aorta from its root to the 
abdominal segment (1, 2). Experimental studies reveal that aortic 
aneurysm is associated with compromised smooth muscle func-
tion, extracellular matrix (ECM) degradation, and increased vascu-
lar inflammation associated with leukocyte infiltration (2–6). This 
pathologic aortic milieu culminates with weakening of the vessel 
wall, a central characteristic of aortic aneurysm disease. Abdominal 
aortic aneurysm (AAA) is usually asymptomatic; however, rupture 
of an aortic aneurysm constitutes an important cause of mortality 
in the elderly that causes more than 15,000 deaths annually in the 
United States (WISQARS Leading Causes of Death Reports (1999–
2013); http://webappa.cdc.gov/sasweb/ncipc/leadcaus10_us.html). 
Despite the risk of mortality associated with AAA, there are no cur-
rent drug therapies that have been shown to limit AAA development 
or progression (7). Currently, timely open or endovascular surgical 
repair remains the only form of treatment (8). Therefore, the eluci-
dation of the cellular and molecular basis for this disease is impera-
tive for the development of novel pharmacologic therapies and 
management strategies.
In addition to providing structural support to the vasculature, 
the ECM is indispensable in modulating cellular signaling and 
vessel performance (9, 10). This ECM milieu dictates organismal 
health, while perturbation of ECM homeostasis is implicated in 
the development of pathological conditions, including atheroscle-
rosis, restenosis, and AAA, with ECM proteins, such as collagen, 
elastin, and integrins, serving an essential role in mediating dis-
ease progression (11). However, despite considerable progress, 
identification of the molecular mechanisms underlying the ECM-
dependent modulation of vascular wall homeostasis in AAA initia-
tion and progression remains incomplete.
CCN (Cyr61, Ctgf, Nov) proteins are a group of secreted ECM-
associated, partially identical cysteine-rich proteins that mediate 
diverse biologic functions (12–14). Although accumulating evi-
dence demonstrates that the CCN gene family is critical to cell 
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rial available online with this article; doi:10.1172/JCI82337DS1), 
CCN3 expression was detected in both arterial and venous SMCs 
from multiple vascular beds. To gain initial insights into the func-
tion of CCN3 in vascular disease, we assessed endogenous CCN3 
expression in the abdominal aortic tissues from experimental AAA 
models. This included Ang II infusion in apolipoprotein E–defi-
cient (Apoe-null) mice and elastase perfusion in C57BL/6 mice, 
both of which share some similarities to human AAA disease. As 
shown in Figure 1A, CCN3 protein was markedly reduced in rodent 
abdominal aorta tissues following 4 weeks of Ang II infusion. 
Moreover, infusion of Ang II caused a time-dependent decrease of 
CCN3 expression (Supplemental Figure 2A). Similar findings were 
obtained in an elastase perfusion model (Supplemental Figure 2B). 
We next assessed CCN3 expression in infrarenal aortic biopsies 
taken from AAA patients and nonaneurysmal controls. Concordant 
with findings in mouse AAA tissues, a dramatic reduction of CCN3 
mRNA expression was seen in human AAA tissues compared with 
control aorta tissues (Figure 1B), findings that were confirmed in 
a previously published microarray data set (19). Finally, CCN3 
protein was reduced in the AAA tissues, as revealed by immuno-
staining (Figure 1, C and D). Of note, costaining of smooth muscle 
α-actin (SMA) and CCN3 suggested a reduction of CCN3 in SMCs 
(Figure 1C). Collectively, these data demonstrate that CCN3 is 
expressed in the aorta and that its expression is reduced in AAA.
growth and differentiation, the physiological importance of CCN 
proteins in the vasculature remains largely undefined. A member 
of this gene family, CCN3 (also known as NOV), was originally 
isolated from nephroblastoma tissue in newborn chicks infected 
with the MAV-1 avian retrovirus (15). Recent studies suggest CCN3 
regulates vascular function (16, 17). However, whether alterations 
of CCN3 expression or function play a causal role in AAA disease 
remains unknown. In the current study, we utilized 2 established 
models of aortic aneurysm (angiotensin II [Ang II] infusion and 
elastase perfusion) to address whether CCN3 is required to regu-
late AAA pathobiology. Herein, we provide evidence that CCN3 
serves as a negative regulator of AAA initiation and progression 
by ameliorating inflammatory cell infiltration, smooth muscle cell 
(SMC) apoptosis, and elastin degradation through a mechanism 
involving the ERK1/2 pathway. Our studies offer insights regarding 
the regulation of AAA formation by CCN3 and provide the founda-
tion for the development of future therapeutics for this disease.
Results
Reduction of CCN3 in rodent and human AAA tissues. Previous stud-
ies suggest that CCN3 is expressed in SMC and endothelial cells 
(ECs) (16–18). To gain a broader understanding, we first assessed 
CCN3 expression in the vasculature of WT mice by immunohisto-
chemistry. As shown in Supplemental Figure 1 (supplemental mate-
Figure 1. CCN3 expression is reduced in AAA. (A) Western blot of CCN3 protein in mouse abdominal aorta tissue from Apoe-null mice infused with saline 
or Ang II for 4 weeks. n = 5–6. (B) CCN3 mRNA expression from human abdominal aorta tissue without and with AAA, n = 5–6 per group, Mann-Whitney U 
test. Representative image of CCN3 protein expression by immunofluorescence staining (C) and quantification from control human nonaneurysmal infra-
renal aorta and AAA (D). Scale bars: 50 μm. Red, SMA; green, CCN3; orange, overlay of SMA (red) and CCN3 (green). Mann-Whitney U test.
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WT littermate controls (both on C57BL/6 backgrounds) were 
subjected to elastase or normal saline perfusion. Consistent with 
our hypothesis, CCN3-deficient animals were more susceptible 
to abdominal aortic dilation following elastase perfusion (Sup-
plemental Figure 3, A and B). To quantify the changes in aorta 
dilation following elastase perfusion, the external infrarenal 
abdominal aortic diameter was measured 14 days after elastase 
perfusion. As shown in Supplemental Figure 3C, at the end of the 
perfusion, the mean external infrarenal abdominal aortic diam-
eter was 0.98 ± 0.04 mm in WT mice, which was significantly 
smaller than that in the CCN3-deficient mice (1.29 ± 0.09 mm, 
P = 0.006, Supplemental Figure 3C). Concordant with this, the 
mean maximal increase in infrarenal aortic diameter following 
elastase infusion in the CCN3-deficient mice was significantly 
greater than in the WT controls (WT: 86.01% ± 7.67%, versus KO: 
140.60% ± 16.47%; P = 0.004, Supplemental Figure 3C).
We next sought to confirm the above findings in a second 
model of AAA formation that involved Ang II infusion, a model 
that recapitulated some human AAA pathological characteristics, 
including inflammatory response and reactive oxygen species 
(ROS) generation within the arterial wall (21–23). Age-matched 
male WT and CCN3-deficient mice were subjected to either 
saline or Ang II (1000 ng/kg/min) infusion for 28 days. With 
saline infusion, we observed no gross differences in morphology 
between the aortas of WT and CCN3-deficient mice. Addition-
ally, electron microscopy studies showed no obvious differences 
in aortic elastin density between WT and CCN3-deficient mice 
Genetic ablation of CCN3 results in aggressive AAA formation. 
Given the observation that CCN3 expression is reduced in AAA, 
we hypothesized that CCN3 deficiency may exacerbate AAA for-
mation. To test this, we first carried out CCN3 loss-of-function 
studies using a model of AAA formation that involves elastase 
perfusion (20, 21). CCN3-deficient mice are healthy, with no 
alterations in growth, reproduction, or tissue morphology (17). 
In these studies, 8- to 10-week-old male CCN3-deficient and 
Figure 2. CCN3 deficiency augments experimentally induced AAA in mice. 
(A) Representative image of whole aortae from WT and CCN3-deficient 
mice following 4 weeks of saline or Ang II infusion. Scale bars: 2.5 mm. 
(B) Representative ultrasound images from WT and CCN3-deficient mice 
following 4 weeks of saline or Ang II infusion. (C) Maximal abdominal aortic 
diameter (left panel), AAA incidence (right panel). Saline treatment, WT,  
n = 11; KO, n = 13. Ang II treatment, WT, n = 38; KO, n = 49. *P < 0.05, WT 
saline versus WT, Ang II; #P < 0.001, WT Ang II versus KO Ang II. (D) Kaplan-
Meier survival curve (left panel, P = 0.06, log-rank test) and AAA classifica-
tion (right panel) in WT versus CCN3-deficient aortae following 4 weeks 
of saline or Ang II infusion. (E) H&E staining of abdominal aorta samples 
from WT and CCN3-deficient aortas following 4 weeks of saline or Ang II 
infusion. Arrow indicates intramural hematoma. Scale bar: 100 μm. (F) Rep-
resentative TER119 staining in WT versus CCN3-deficient aortae following 
28 days of saline or Ang II infusion. Scale bars: 50 μm. (G) Elastin integrity 
grading in WT versus CCN3-deficient aortae following 4 weeks of saline or 
Ang II infusion. Data are presented as mean ± SEM. Saline group, WT, n = 5; 
KO, n = 7. Ang II group, WT, n = 7; KO, n = 12. WT, Ccn3+/+; KO, Ccn3–/–. Scale 
bar: 50 μm. For comparing AAA incidence, χ2 test was used. In all others, 
2-way ANOVA followed by Bonferroni’s post-hoc correction was used.
Figure 3. CCN3 deficiency promotes 
a proinflammatory response. 
Representative images of immu-
nohistochemical staining for 
macrophages (MAC3) (A), T cells 
(CD3) (B), MCP1 (C), and VCAM1 (D) 
in WT versus CCN3-deficient aortae 
following 28 days of Ang II infusion; 
quantification shown in the right 
panels. Saline, n = 3; Ang II, n = 5–6. 
Two-way ANOVA followed by Bon-
ferroni’s test. Scale bars: 100 μm.
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28 days developed generalized aortic dilation (Figure 2, A and 
C). The mean maximal suprarenal abdominal aortic diameters 
of aortas in the CCN3-deficient mice were significantly greater 
than those of the WT controls (WT: 1.25 ± 0.07 mm, n = 38, versus 
CCN3-deficient: 2.04 ± 0.08 mm, n = 49; P < 0.001). Adopting 
a binary scoring system, more than 70% of Ccn3–/– mice devel-
oped AAAs, while less than 16% of WT mice developed AAA (P < 
0.001, Figure 2C). The AAA phenotype of CCN3-deficient mice 
after Ang II infusion was also manifested by ultrasound imaging 
that confirmed the finding that CCN3-deficient mice had a larger 
(Supplemental Figure 4). Moreover, CCN3-deficient aortas dem-
onstrated no medial hypertrophy and there was no significant dif-
ference in blood pressure between WT and CCN3-deficient mice 
under basal and following Ang II infusion (ref. 17 and data not 
shown). Additionally, there was no difference in the lipid profile 
of WT and CCN3-deficient mice after 4 weeks of Ang II infusion 
(Supplemental Figure 5). However, in response to 28 days of Ang 
II infusion, the aortas from CCN3-deficient mice displayed exqui-
site sensitivity, findings that were in agreement with the elastase 
perfusion model. CCN3-deficient mice infused with Ang II for 
Figure 4. CCN3 deficiency promotes MMP production in CCN3-deficient aortas following 4 weeks of Ang II infusion. (A) Immunohistochemical staining 
for MMP2 and (B) MMP9; quantification shown in the right panel. Saline, n = 3; Ang II, n = 5–7. Representative images for saline-infused group are shown 
in Supplemental Figure 7. (C) Plasma MMP2 and MMP9 levels analyzed by ELISA (n = 3 for saline group; WT Ang II, n = 6; KO Ang II, n = 12). (D) MMP 
activity in abdominal aortic protein lysates by zymography (saline, n = 3; Ang II, n = 8). Pro-MMP2, full-length MMP2. (E) In situ MMP activity, saline,  
n = 3; Ang II, n = 6. Two-way ANOVA followed by Bonferroni’s test. Scale bars: 100 μm.
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abdominal aorta (Figure 2B). In addition, 5 CCN3-deficient mice 
died of aortic rupture, while no such deaths were observed in the 
WT group (Figure 2D). We further classified AAA formation in WT 
and CCN3-deficient mice based on the severity of AAA as sug-
gested by Daugherty and colleagues (24). Using this classification 
system, CCN3-deficient mice developed more severe AAAs than 
WT mice (Figure 2D).
To assess the histological features of the AAAs, we performed 
H&E and elastin staining. Histologic examination revealed intra-
mural hematoma formation in the aneurysmal tissues. As shown 
in Figure 2, E and F, the presence of red blood cells within the aor-
tic wall of CCN3-deficient mice was evidenced by H&E staining as 
well as immunostaining for TER119 (marker for red blood cells). 
Additionally, the aortas of CCN3-deficient mice that received Ang 
II were characterized by severe disruption of medial architecture 
with prominent elastin degradation, which is another key feature 
of AAA. Profoundly disrupted and fragmented elastic lamellae 
were seen in the aortas of CCN3-deficient mice, as demonstrat-
ed by Verhoeff–van Gieson staining (Figure 2G). Similarly, dra-
matic elastin degradation was observed in the aortas of elastase- 
perfused CCN3-deficient mice (Supplemental Figure 6A).
Taken together, these data suggest that CCN3-deficient aor-
tas are highly sensitive to experimentally induced AAA forma-
tion (by elastase perfusion or Ang II infusion) and develop aor-
topathy with markedly increased frequency of AAA marked by 
deteriorated ECM, suggesting a protective role of CCN3 against 
AAA formation.
Loss of CCN3 exacerbates vascular inflammation and MMP 
activities. As AAA is typically accompanied by vascular inflam-
mation, we next sought to evaluate whether Ang II infusion gives 
rise to a heightened state of vascular inflammation in CCN3-
deficient mice. One of the hallmark features of both human 
AAA and Ang II–induced AAA in rodents is the accumulation of 
inflammatory infiltrates in both the adventitia and media layers 
Figure 5. CCN3 deficiency promotes ROS generation and loss of SMCs in CCN3-deficient aortas following Ang II infusion. (A) ROS generation 7 days 
after Ang II infusion assessed by DHE staining (saline, n = 3; Ang II, n = 5). (B) ROS generation 4 weeks after Ang II infusion (saline, n = 3; Ang II, n = 5–6). 
(C) SMC TUNEL staining following 7 days of Ang II treatment in WT versus CCN3-deficient aortas (saline, n = 3; Ang II, n = 5–6). Green, TUNEL positive; 
blue, DAPI nuclear staining. (D) SMC loss assessed by SMA staining 4 weeks after Ang II infusion in WT versus CCN3-deficient aortas (saline, n = 3; Ang 
II, n = 5–8). Grade 1, intact media, no SMC loss; grade 2, modest loss of SMC; grade 3, severe loss of SMC; grade 4, rupture of media, almost no SMC left. 
Two-way ANOVA followed by Bonferroni’s test. Scale bars: 50 μm.
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(25). As such, we first examined inflammatory cell infiltration. 
In saline-perfused controls, there was minimal inflammatory 
response (Supplemental Figure 7). However, as expected, Ang 
II infusion led to the accumulation of inflammatory cells within 
the aortas of mice, as assessed by MAC3 (macrophage) and CD3 
(T cell) staining (Figure 3, A and B). A more profound inflamma-
tory infiltrate was observed in CCN3-deficient mice (Figure 3, A 
and B). To gain further insights into the inflammatory response, 
immunostaining studies were performed to assess the expres-
sion of several key inflammatory molecules implicated in AAA, 
Figure 6. The AAA phenotype in CCN3-deficient mice is intrinsic to the vascular wall. (A) Maximal external abdominal aortic diameter and (B) AAA 
incidence of BMT mice following Ang II infusion. n = 3–4 for saline group; n = 11–14 for Ang II group. (C) ROS production (assessed by DHE staining) in SMCs 
following Ang II treatment in WT versus CCN3-deficient mice. n = 6 per group. (D) TUNEL staining in cultured SMCs from WT and CCN3-deficient aortas 
following Ang II treatment. n = 5 independent experiments. (E) Mcp1, Icam1, Il6, and Vcam1 mRNA expression in WT versus CCN3-deficient SMCs in the 
absence or presence of Ang II; n = 4 per group. Scale bars: 50 μm. Two-way ANOVA followed by Bonferroni’s post-hoc correction was used.
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ure 8A). We observed a similar enhancement of inflammatory 
response to elastase perfusion in the aortas of CCN3-deficient 
mice (MAC3 staining) (Supplemental Figure 6B).
The infiltration of monocytes and macrophages into the aor-
tic wall acts as a major source of proteolytic enzymes, including 
MMPs and cathepsins, which promote matrix degradation, thus 
impairing the integrity of the arterial wall and favoring aneurysm 
development (20, 26). MMPs such as MMP2 and MMP9 have been 
demonstrated as being critical for ECM remodeling and aneurysm 
including monocyte chemoattractant protein-1 (MCP-1) and 
VCAM-1. Consistent with the hyperinflammatory cell migra-
tion data, substantially greater VCAM-1 and MCP-1 staining was 
observed in the aortas of CCN3-deficient mice after Ang II infu-
sion (Figure 3, C and D). In addition, we performed quantitative 
reverse-transcription PCR (qRT-PCR) experiments using supra-
renal aortic segments. The mRNA expression of Mcp1 and Vcam1 
was significantly increased in the aortas of CCN3-deficient mice 
receiving Ang II compared with controls (Supplemental Fig-
Figure 7. ERK1/2 activation by Ang II is increased in CCN3-deficient aorta. (A) Immunohistochemistry assessment of ERK1/2 activation in CCN3-deficient 
aortae in response to Ang II treatment (7 days and 4 weeks). Representative images are shown on the left; results are quantified on the right. n = 3–5 per 
group. Scale bars: 100 μm. (B) Western blot of phospho-ERK1/2 in aortae following saline or Ang II treatment (4 weeks). n = 4 for saline group; n = 6–8 for 
Ang II group. (C) Western blot of phospho-ERK1/2 and phospho-MEK1/2 in aortae following saline or Ang II treatment (7 days). n = 4 for saline group, n = 6–8 
for Ang II group. (D) Western blot of phospho-ERK1/2 and phospho-MEK1/2 in aortic SMCs following Ang II (30 minutes) treatment. n = 3 for WT, n = 4 for 
KO. T-ERK1/2, total ERK1/2; T-MEK1/2, total MEK1/2. Two-way ANOVA followed by Bonferroni’s post-hoc correction was used.
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increased expression of p47Phox and cyclophilin A within the 
suprarenal abdominal aorta of CCN3-deficient mice (Supple-
mental Figure 10B). Both of these proteins have been implicated 
in generating ROS. Similar effects on 4-HNE are observed in the 
elastase perfusion model (Supplemental Figure 6D).
Healthy SMCs within the aortic media are important for nor-
mal vessel function. Aortic SMC apoptosis is a hallmark of human 
AAA (29). The CCN family of proteins has been shown to play a 
critical role in cell survival (12, 13). We therefore hypothesized that 
loss of CCN3 may promote exaggerated SMC apoptosis under the 
status of increased inflammation and elevated ROS seen in CCN3-
deficient mice after Ang II infusion. In the saline-infused animals, 
we observed minimal TUNEL staining in both control and CCN3-
deficient mice. After 7 days of Ang II infusion, marked TUNEL 
staining was observed in the aortic media of the CCN3-deficient 
mice (Figure 5C). In line with this observation, we found a marked 
difference in the staining pattern of SMC marker proteins between 
WT and CCN3-deficient mice following Ang II infusion. In WT 
controls, there was uniform staining for SMA in medial SMC and 
homogeneous layers of SMCs were separated by elastic laminae 
in an orderly pattern. In marked contrast, CCN3-deficient mice 
displayed a disrupted medial SMC layer with a dramatic paucity in 
SMA, suggesting a significant loss of SMC at 28 days after Ang II 
infusion (Figure 5D).
ROS are required for AAA formation in CCN3-deficient 
mice. Given the more profound ROS formation in the aortas of 
CCN3-deficient mice following Ang II infusion, we next sought 
to determine the causal role of ROS in the formation of AAA in 
CCN3-deficient mice. To address this question, pharmacological 
inhibition studies were employed using apocynin, an antioxidant 
that has been applied in a number of in vivo experimental studies 
for the purpose of inhibiting ROS production. Prior to AAA induc-
tion with Ang II infusion, 2 groups of male CCN3-deficient mice 
(n = 12 per group) were administered water or apocynin (100 mg/
kg/d) for 1 week. Next, all mice were subjected to Ang II infusion 
with continuous water or apocynin administration for 28 days. 
The efficacy of apocynin in limiting ROS was confirmed by DHE 
staining (Supplemental Figure 11A). As expected, the majority 
of CCN3-deficient mice (66%) receiving water developed AAA. 
However, a strong reduction of AAA incidence was observed in 
CCN3-deficient mice receiving apocynin (25%) (Supplemental 
Figure 11B). Furthermore, antioxidant application dramatically 
attenuated the major pathological features observed in CCN3-
deficient mice receiving water. As demonstrated in Supplemen-
tal Figure 11B, we observed a significant decrease in the maximal 
abdominal aortic diameter. Moreover, addition of apocynin to 
the drinking water preserved the vessel wall integrity evidenced 
by elastin staining (Supplemental Figure 11C), reduced the infil-
tration of macrophage by 66% (Supplemental Figure 11D), and 
diminished MMP activity by 50% (Supplemental Figure 11E). 
Finally, apocynin administration significantly mitigated Ang II–
induced ERK1/2 activation in CCN3-deficient mice (Supplemen-
tal Figure 11F). Collectively, these studies indicate ROS generation 
is a major contributor to AAA formation in CCN3-deficient mice.
AAA formation in CCN3-deficient mice is intrinsic to the vessel 
wall. Our studies revealed an inhibitory role for the matrix-asso-
ciated protein CCN3 in experimental AAA formation. However, 
formation in experimental studies (20, 27). Given the severe elas-
tin degradation observed in CCN3-deficient aortas (Figure 2G), 
we postulated that MMP expression was upregulated. As shown in 
Figure 4, A and B, and Supplemental Figure 8B, a marked increase 
of MMP2 and MMP9 was observed at both the protein and mRNA 
levels in the suprarenal abdominal aortas of CCN3-deficient mice 
following Ang II infusion. A similar augmentation of MMP2 was 
observed in the abdominal aortas of CCN3-deficient mice per-
fused with elastase (Supplemental Figure 6C). Consistent with the 
above findings, we observed a significant increase of MMP2 and 
MMP9 in the plasma of CCN3-deficient mice in response to Ang 
II infusion (Figure 4C). To determine whether altered MMP levels 
translate into proteolytic activity, we also evaluated MMP activity 
in aortic lysates from WT and CCN3-deficient mice by zymogra-
phy. Consistent with the increase in MMP expression, consider-
ably heightened MMP activity was observed in aortas of CCN3-
deficient mice compared with WT controls after Ang II infusion 
(Figure 4D). These results were further corroborated with in situ 
MMP activity assessment of aortic sections (Figure 4E).
In summary, these studies suggested that following Ang II 
infusion, the aortas of CCN3-deficient mice were characterized 
by an enhanced inflammatory state associated with elevated 
MMP activity.
Enhanced generation of ROS and loss of SMCs in CCN3-deficient 
mice in experimental AAA. Evidence from animal and human stud-
ies suggests that oxidative stress as a key mediator in the patho-
genesis of AAA (28). ROS have been shown to play a key role in 
the regulation of MMPs and induction of SMC apoptosis (28). We 
therefore assessed oxidative stress. Abdominal aortic sections 
from Ang II– and saline-infused WT and CCN3-deficient mice 
were incubated with dihydroethidium (DHE). As expected, in 
saline-infused mice, both WT and CCN3-deficient aorta demon-
strated minimal evidence of ROS. However, Ang II infusion for 7 
days triggered a dramatic increase in markers of superoxide gen-
eration, with this effect being more pronounced in the absence 
of CCN3 (Figure 5A). Similar effects were observed following 
28 days of Ang II infusion (Figure 5B and Supplemental Figure 
9). The generation of ROS was also confirmed by the measure-
ment of 4-hydroxynonenal (4-HNE), a major end product of lipid 
peroxidation. As shown in Supplemental Figure 10A, enhanced 
4-HNE levels were observed in the aortas of CCN3-deficient mice 
compared with WT controls after Ang II infusion. There was also 
Figure 8. ERK1/2 pathway contributes to AAA formation in CCN3-
deficient mice. (A) Maximal abdominal aortic diameter (left panel) and 
AAA incidence (right panel) in response to pharmacological inhibition of 
ERK1/2 by CI-1040 and JNK1/2 by SP600125 in KO mice. n = 5 for saline 
group; n = 13 for WT with Ang II; n = 22 for KO mice with Ang II; n = 20 for 
KO mice plus CI1040 group; n = 15 for KO mice plus SP600125 group. (B) 
Analysis of genetic inhibition of Erk1 on maximal abdominal aortic diame-
ter (left panel) and AAA incidence (right panel) using Ccn3/Erk1 double-KO 
mice: Left panel, decrease of aortic expansion with Ang II treatment; right 
panel, AAA incidence, Ccn3–/–, n = 21; Ccn3–/– Erk1–/–, n = 18. Evaluation of 
elastin degradation (Ccn3–/–, n = 17; Ccn3–/– Erk1–/–, n = 7) (C), ROS produc-
tion (Ccn3–/–, n = 5; Ccn3–/– Erk1–/–, n = 6) (D), MMP activity (Ccn3–/–, n = 9; 
Ccn3–/– Erk1–/–, n = 10) (E), and macrophage infiltration (n = 9) (F) in Ccn3/
Erk1 compound-KO mice following Ang II infusion. Scale bars: 100 μm. For 
comparing AAA incidence, χ2 test was used; for all others, 2-way ANOVA 
followed by Bonferroni’s post-hoc correction was used.
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CCN3 on cellular ROS generation, apoptosis, and inflammatory 
response. Toward this end, we used primary mouse aortic SMCs 
isolated from control and CCN3-deficient mice. We first assessed 
whether loss of CCN3 affects ROS production. Murine vascular 
SMCs were serum deprived for 24 hours, which was followed by 
exposure to vehicle or Ang II for 24 hours. We then assessed ROS 
generation by DHE staining. As shown in Figure 6C, CCN3 defi-
ciency resulted in augmented ROS production in SMCs, findings 
consistent with our in vivo observations in the vessel wall. Given 
these observations coupled with the profound impact of ROS on 
SMC apoptosis, we next tested the effect of CCN3 deficiency 
on SMC survival. Here, SMCs received vehicle or Ang II and the 
degree of apoptosis was analyzed by a TUNEL assay. As shown 
in Figure 6D, Ang II administration resulted in apoptosis of WT 
SMCs; however, in the absence of CCN3, Ang II administration 
caused exacerbated apoptosis of SMCs. The findings were consis-
tent with enhanced apoptosis in SMCs observed in the aortic wall 
after Ang II administration (Figure 5C). In addition, we analyzed 
mRNA levels of several inflammatory markers (Mcp1, Icam1, Il6, 
and Vcam1) from vascular SMCs receiving Ang II. qPCR results 
indicated that loss of CCN3 resulted in enhanced Mcp1, Icam1, 
Il6, and Vcam1 expression (Figure 6E). These data suggest a pro-
inflammatory state in the CCN3-deficient SMCs. Conversely, 
adenoviral-mediated overexpression of CCN3 in rat aortic SMCs 
(RASMCs) significantly reduced ROS generation as well as Mcp1, 
Icam1, Il6, and Vcam1 expression (Supplemental Figure 13, A and 
B). Taken together, our results indicate that alterations of CCN3 
in vascular SMCs cause multiple functional changes, support-
ing the notion that loss of vascular SMC-derived CCN3 plays an 
important role in AAA formation.
Pharmacological and genetic inhibition of the ERK1/2 pathway 
mitigates Ang II–induced AAA formation in CCN3-deficient mice. 
Mechanistic studies over the last several decades have focused 
on key signaling pathways underlying AAA initiation and progres-
sion, including MAPKs, NF-κB, TGFB, STAT, and mTOR (30–37). 
These pathways have been shown to regulate vascular inflamma-
tion, ROS elaboration, cell survival, and vessel wall integrity. In 
an effort to glean mechanistic insights into the underlying cause 
of AAA pathology in CCN3-deficient mice, we first surveyed sev-
eral MAPK and TGFB signaling pathways. Protein lysates from 
Ang II–infused abdominal aortas as well as aortic sections were 
subjected to Western blot and immunohistochemistry analysis. 
As shown in Supplemental Figure 14, these studies indicated that 
CCN3 deficiency does not affect Smad2 phosphorylation (indica-
tive of the TGFB pathway), the JNK pathway, the NF-κB path-
way, or p38 kinase. However, we observed a profound activation 
of ERK1/2 signaling in CCN3-deficient aortas, as evidenced by 
marked enhancement of ERK1/2 phosphorylation at both 7 days 
and 4 weeks after Ang II infusion by both immunohistochemical 
and Western blot analyses (Figure 7, A–C). In addition, a signifi-
cantly heightened activation of MEK1/2 (the upstream activator 
of ERK1/2) was observed in CCN3-deficient aortas (Figure 7C). 
Furthermore, immunohistochemistry studies revealed a more 
robust ERK1/2 phosphorylation in the media of CCN3-deficient 
aortas (Supplemental Figure 15). A similar enhanced activation 
of ERK1/2 was observed in CCN3-deficient aortas following 
elastase perfusion (Supplemental Figure 16). Finally, Western 
these observations were performed in CCN3 systemic KO mice — 
an approach that precludes precise determination of the cellular 
contributor(s) within or outside of the vessel wall responsible for 
the AAA phenotype in vivo. To address this, we performed recipro-
cal BM transplantation (BMT) experiments. For these BMT stud-
ies, 12-week-old male mice were irradiated; this was followed by 
tail-vein injection of marrow from WT or CCN3-deficient mice. 
The experimental strategy is shown in Supplemental Figure 12. 
Transplanted mice were allowed 6 weeks of engraftment and 
were then subjected to Ang II infusion (1,000 ng/kg/min) for 
an additional 28 days, at which time aortas were harvested and 
assessed for AAA development. We first assessed AAA formation 
using CCN3-deficient marrow as donor. These studies confirmed 
the development of severe AAA formation in 70% of CCN3-defi-
cient animals following 28 days of Ang II infusion, while CCN3-
deficient marrow reconstitution did not alter AAA development 
in WT mice. The mean maximal abdominal aortic diameter was 
2.12 ± 0.24 mm in the CCN3-deficient group (n = 11) receiving 
CCN3-deficient marrow, which is significantly bigger than that of 
the WT group transplanted with CCN3-deficient marrow (1.30 ± 
0.09 mm, n = 11, Figure 6A). These results strongly suggest that 
the AAA phenotype of CCN3-deficient mice is intrinsic to the 
vasculature. This notion is further substantiated by reverse BMT 
studies using WT as a donor. As shown in Figure 6, A and B, WT 
marrow did not alter the severity of AAA in CCN3-deficient mice. 
The maximal abdominal aortic diameter of CCN3-deficient mice 
receiving WT marrow was 1.9 ± 0.29 mm (n = 12), which was sig-
nificantly larger than that of WT mice receiving WT marrow (1.22 
± 0.04 mm, n = 14, Figure 6A). In summary, these BMT studies 
support the hypothesis that vascular CCN3 plays a critical role in 
mediating the AAA phenotype.
The aortic wall is composed of 3 layers: the intima, com-
posed of endothelial monolayer and underlying extracellular 
connective tissues; the media, consisting primarily of SMCs; and 
the outermost layer, the adventitia, containing fibroblasts and 
collagens, proteoglycans, and vasa-vasorum. Given the central 
importance of SMCs in the development of AAA coupled with the 
knowledge that CCN3 is highly expressed in SMCs of the aortic 
wall (Supplemental Figure 1), we hypothesized that alterations of 
CCN3 in SMCs may regulate key aspects of AAA pathology. We 
therefore next sought to determine the effects of SMC-derived 
Figure 9. CCN3 overexpression inhibits elastase-induced AAA formation. 
(A) Confirmation of lentiviral CCN3 overexpression by Western blot. Left 
panel, representative Western blot showing CCN3 overexpression after 
2 weeks of lentivirus injection; right panel, quantitation data for CCN3 
Western blot (n = 5). (B) Infrarenal abdominal aortic dilatation 2 weeks 
after elastase perfusion in control (control lentivirus [Lenti-Con], n = 7) ver-
sus CCN3 overexpression (Ccn3 lentivirus [Lenti-Ccn3], n = 9). Left panel, 
inhibition of external infrarenal aortic diameter; right panel, percentage 
of aortic diameter increase (Lenti-Con, n = 7; Lenti-Ccn3, n = 9). (C) Elastin 
staining by Verhoeff–van Gieson in abdominal aorta following elastase 
perfusion in control (n = 7) versus Ccn3 overexpression aortae (n = 9). 
Assessment of MMP activity by in situ zymography (n = 5) (D); macrophage 
infiltration by immunostaining (Lenti-Con, n = 5; Lenti-Ccn3, n = 9) (E); 
ROS production by DHE staining (n = 6 per group) (F); and ERK1/2 activa-
tion by immunohistochemical analysis (Lenti-Con, n = 7; Lenti-Ccn3, n = 6) 
(G). Scale bars: 100 μm. Two-way ANOVA followed by Bonferroni’s post-hoc 
correction was used.
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lenti-Ccn3 virus (1.0 × 108 IFU [infectious units]/mouse). One day 
prior to lentivirus injection, mice were subjected to elastase perfu-
sion as described in Methods. Mice were then injected with lentivi-
rus on the following day. Two weeks later, AAA extent and sever-
ity were evaluated by ultrasound, morphology, and biochemistry. 
CCN3 overexpression in the vessel was verified by Western blot 
(Figure 9A). Using this approach, systemic delivery of lenti-CCN3 
resulted in 2.0-fold CCN3 overexpression in the aorta. Strikingly, 
sustained CCN3 expression in vivo strongly blunted the progres-
sion of AAA induced by elastase perfusion. Following 2 weeks of 
elastase perfusion, the maximum aortic diameter increased by 
127.3% ± 13.73% (n = 7) in the control virus group compared with 
baseline. However, the extent of aortic dilation was significantly 
lower in the CCN3 overexpression group (72.32% ± 6.59%, n = 9, 
P = 0.003, Figure 9B). The severity of elastin destruction was also 
much less pronounced in the CCN3-overexpressing mice (Figure 
9C), consistent with the markedly reduced MMP activity in these 
mice (Figure 9D). We then analyzed macrophage infiltration and 
ROS production. As shown in Figure 9, mice with CCN3 overex-
pression exhibited a significant reduction in macrophage infil-
tration (Figure 9E) and ROS generation (Figure 9F). Finally, to 
complement loss-of-function studies where heightened ERK1/2 
signaling in CCN3-deficient aorta was observed, we assessed for 
ERK1/2 phosphorylation in the setting of CCN3 overexpression. 
As evidenced by immunohistochemistry data, sustained CCN3 
expression markedly diminished ERK1/2 activation (Figure 9G), 
supporting the notion that the CCN3 suppression of AAA is, at least 
in part, through a mechanism involving ERK1/2 signaling inhibi-
tion. These results suggest that lentivirus-mediated CCN3 over-
expression is sufficient to prevent AAA progression in the elastase 
perfusion model. To determine whether a similar inhibitory effect 
could be achieved in the Ang II model, we carried out studies using 
adenovirus-mediated overexpression, an approach that has been 
successfully used during Ang II infusion into Apoe-null mice (42). 
Control and CCN3 adenovirus were administered locally to the 
suprarenal aorta of Apoe-null mice, followed by Ang II infusion the 
next day. Mice were sacrificed at day 14 after Ang II infusion and 
abdominal aortic dilation evaluated. As shown in Supplemental 
Figure 18, adenoviral overexpression of CCN3 significantly ame-
liorated Ang II–mediated abdominal aortic expansion, further cor-
roborating that CCN3 is able to prevent AAA progression.
Discussion
Previous studies demonstrate that CCN proteins control key cel-
lular processes, such as apoptosis, senescence, mitosis, adhesion, 
ECM production, differentiation, proliferation, growth arrest, 
and migration (13, 43). Given these roles, it is not surprising that 
aberrant expression of CCN proteins has been implicated in the 
pathobiology of a wide array of diseases, including cancer, dia-
betic nephropathy, and systemic sclerosis (13). With regard to the 
cardiovascular system, a causal role for the CCN family of proteins 
in arterial pathology has not been previously demonstrated. Our 
studies reported here thus provide what we believe to be novel 
evidence implicating CCN3 in the pathobiology of AAA. This is 
supported by a number of observations. First, we show that CCN3 
expression is attenuated in both human and rodent AAA tissues. 
Next, genetic ablation of CCN3 exacerbates vascular dilation and 
blot analysis was performed to assess whether CCN3 deficiency 
affects ERK1/2 signaling in SMCs. Following Ang II administra-
tion, we observed elevated ERK1/2 activation and its upstream 
regulator MEK1/2 in CCN3-deficient SMCs compared with 
WT SMCs (Figure 7D). Conversely, overexpression of CCN3 in 
RASMC significantly inhibited ERK1/2 and MEK1/2 phosphory-
lation (Supplemental Figure 13C). These observations prompted 
us to hypothesize that ERK1/2 activation may govern the effects 
of AAA formation in CCN3-deficient mice.
To determine whether ERK1/2 activation plays a causal role in 
AAA observed in CCN3-deficient mice, we undertook both phar-
macological and genetic inhibition approaches. Our first approach 
was to utilize CI-1040, an inhibitor of MEK that has been widely 
used in animal studies. CCN3-deficient mice (n = 12) were pretreat-
ed with vehicle or CI-1040 (100 mg/kg/d) by gavage for 3 days. 
Thereafter, all mice were infused with Ang II for 28 days. During 
the ensuing Ang II infusion period, the 2 groups of mice continu-
ally received daily oral gavage of vehicle or CI-1040. In light of the 
reported inhibitory effects on AAA development in rodents (30), 
we performed a parallel experiment using a JNK pathway inhibitor, 
SP600125. Western blotting was performed to verify the success-
ful inhibition of ERK1/2 activation (Supplemental Figure 17). Upon 
completion of Ang II infusion, blockade of ERK1/2 signaling miti-
gated the CCN3-dependent Ang II induction of AAA formation 
and AAA incidence, as demonstrated by diminished abdominal 
aortic dilation (Figure 8A). Interestingly, JNK inhibition caused a 
mild reduction of aorta expansion, but the effects were not signifi-
cant (Figure 8A), indicating JNK activation does not play a major 
role in the AAA pathology of CCN3-deficient mice.
In order to further corroborate our findings garnered from 
these pharmacological inhibition studies, we also carried out stud-
ies with genetic inactivation of ERK1 in CCN3-deficient mice. 
Erk1-KO mice are viable, whereas Erk2 deficiency is embryonically 
lethal (38), thus precluding us from including Erk2-null mice in this 
study. We backcrossed CCN3-deficient mice onto Erk1-KO mice 
(both on C57BL/6 background). Subsequently, both CCN3-defi-
cient and CCN3/ERK1 compound-KO mice underwent 28 days 
of Ang II infusion and AAA phenotype was assessed. In marked 
agreement with the results from the pharmacological inhibition 
experiments, genetic inactivation of ERK1 dramatically reduced 
AAA incidence and severity, as assessed by maximal aortic diam-
eter and elastin breakdown in the vessel wall (Figure 8, B and C). 
Moreover, loss of ERK1 signaling strongly reversed ROS produc-
tion, MMP activity, and macrophage infiltration (Figure 8, C–F). 
Collectively, these findings indicate that hallmark features of AAA 
phenotype in CCN3-deficient aortas are ERK1/2 dependent.
Virus-mediated overexpression of CCN3 is sufficient to prevent 
AAA development in a murine AAA model. As presented above, data 
derived from our loss-of-function studies strongly implicate CCN3 
as playing an important role in the pathogenesis of aortic aneu-
rysm. An important question that remains is whether sustained 
CCN3 expression in animals confers salutary effects on the devel-
opment of AAA. We first tested the effects of overexpression in the 
elastase perfusion model. To achieve sustained CCN3 expression 
in vivo, we adopted a lentivirus-mediated overexpression approach 
that has been successfully employed by a number of groups (39–
41). We performed tail-vein injection of either control lentivirus or 
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deficient mice. Indeed, there are an abundance of signaling path-
ways, including Rho/ROCK, p53, PI3K/Akt, NOTCH, AMPK, and 
STAT, known to be critical in AAA pathology that were not inves-
tigated in the current study, but that may also play an important 
role in AAA pathology (25, 33, 54–60). For example, SMC-derived 
AMPK-α2 has been shown to be critical for nicotine- and Ang II–
mediated AAA progression and abrogation of AMPK-α2 blunts 
AAA formation (60). KO of Akt2 also exacerbates AAA formation 
(61). Thus, the potential role of CCN3 in altering these pathways in 
AAA formation requires further investigation.
Another important question of this study relates to the cel-
lular contributor or contributors responsible for the AAA pheno-
type. Considering that both vascular resident cells and recruited 
myeloid-derived inflammatory cells contribute to the vascular 
inflammatory response and matrix degradation (2 key drivers in 
the formation of AAA), we performed reciprocal BMT experiments. 
Although our reciprocal BMT experiments point to the importance 
of vessel-derived CCN3 in conferring protection from AAA forma-
tion, this approach does not distinguish between the vascular wall 
and other somatic tissues. This limitation also applies to our sys-
temic delivery of CCN3 using a viral approach in the overexpres-
sion studies, in which the hepatic expression of CCN3 is likely to 
increase, which could potentially affect the overall physiology of 
the animals. Furthermore, there are 3 cell types within the vessel 
wall: ECs, vascular SMCs, and adventitial fibroblasts. Given their 
central importance in vascular structure and function, SMCs have 
been the most studied cell type for gaining mechanistic insights 
involved in AAA formation. We therefore assessed the effects of 
alteration of CCN3 levels on SMC function. Our in vitro studies 
using cultured SMCs indeed support the important role of CCN3 
in regulating inflammation, ROS, and ERK1/2 signaling (Figure 4 
and Supplemental Figure 13). However, these results do not pro-
vide definitive proof of the importance of SMC. Additionally, it is 
noteworthy CCN3 is expressed in the hematopoietic compartment 
(62, 63). Therefore, future studies using tissue-specific Ccn3-KO 
mice are warranted to definitively determine the precise cellular 
contributor or contributors in AAA pathology.
Our studies suggest clinical relevance of CCN3 to AAA. We 
found a marked reduction of CCN3 in human AAA tissues in com-
parison with age- and sex-matched nonaneurysmal abdominal 
aorta, implicating the relevance of alterations of CCN3 expression 
in human aneurysm formation. To characterize the role of CCN3 
in the pathogenesis of AAA, the current study utilized 2 established 
rodent models to examine the effects of germline deficiency of 
Ccn3 on AAA formation, both of which recapitulate human AAA 
pathology. The Ang II infusion model is known to elicit AAAs with 
some features of human AAA, including dramatic aortic dilatation 
with aneurysm formation, aortic media destruction, and inflam-
matory cell recruitment and infiltration as well as ROS and MMP 
expression (22). The AAA phenotype in CCN3-deficient mice 
remarkably resembles the above-mentioned features in human 
AAA. However, one limitation to this model is that AAA developed 
in the suprarenal aorta, whereas human AAA usually occurs in the 
infrarenal aorta. To circumvent this issue and to more closely mir-
ror the human AAA, we adopted the elastase perfusion model. The 
advantage of this model is that an aneurysm is formed in the infra-
renal aorta. The finding that CCN3 deficiency promotes AAA in 
elastolysis in rodent AAA models. Further, our results demon-
strate that CCN3 is a negative regulator of multiple key pathologi-
cal processes involved in aneurysm formation, including oxidative 
stress, MMP elaboration, SMC apoptosis, and vascular inflamma-
tion. BMT experiments, coupled with ex vivo cell culture studies, 
support the notion that SMC-derived CCN3 may be an important 
regulator of AAA. Mechanistic studies reveal a role for ERK1/2 
activation in the pathogenesis of AAA in CCN3-deficient mice, 
results corroborated by both pharmacological and genetic inhi-
bition studies. Finally, we show that systemic overexpression of 
CCN3 prevents AAA formation.
The results of this study advance our understanding of CCN 
proteins in vascular biology and offer insights into other vascular 
abnormalities. Recent studies have revealed the roles of CCN pro-
teins in angiogenesis, effects attributed to their interactions with 
integrins (44–46). Alterations of CCN1 and CCN2 expression 
were observed in atherosclerotic lesions, suggesting a potential 
role of these 2 factors in atherosclerosis (47, 48). CCN2 has also 
been previously reported to be upregulated in aneurysmal and 
dissected arteries (49). At the cellular level, several CCN mem-
bers (CCN1, CCN2, CCN3, CCN4) have been shown to regulate 
the synthetic phenotype of SMCs (17, 50–53). Our recent study 
suggests CCN3 is a flow-inducible factor and a negative regula-
tor of endothelial inflammation (16). In our current study, we 
provide evidence to suggest an important role of CCN3 in regu-
lating AAA disease through ROS- and ERK1/2-dependent mech-
anisms, thus establishing the first example, to our knowledge, of 
the involvement of the CCN family in vascular disease. By virtue 
of the versatile ability of matricellular protein CCN3 to impart on 
multiple aspects of vessel pathology, including vascular remod-
eling, inflammation, cell survival, and ROS production, one can 
postulate that CCN3 could modulate an essential stage common 
to many inflammatory diseases such as vasculitis and atheroscle-
rosis. Previous studies on AAA commonly employed dyslipid-
emic mice infused with Ang II. CCN3-deficient mice developed 
AAA in response to Ang II on a nonhyperlipidemic background, 
suggesting that the Ccn3-mutant mice may serve as a model for 
investigating AAA independent of lipid levels.
Given that vascular wall integrity is critical to maintaining 
its function, we further assessed the effect of CCN3 deficiency 
on vascular structure. Histology and electron microscopy studies 
revealed no obvious abnormalities in the aortic wall of Ccn3-defi-
cient mice, suggesting CCN3 does not affect the formation of elas-
tic fibers or affect vascular stability. These findings are in line with 
the current understanding of matricellular proteins, which play a 
minimal role in vascular structure, but are primarily involved in 
the regulation of cellular functions (13).
Next, we investigated the mechanistic basis for the protective 
role of CCN3 in AAA formation by examining multiple signaling 
pathways known to be important for AAA pathogenesis. These sig-
naling pathways are stimulated with Ang II and regulate inflamma-
tory and apoptotic targets. Our genetic and pharmacological stud-
ies suggest that the ERK1/2 pathway is a major regulator of Ang 
II–induced AAA formation in CCN3-deficient mice. However, we 
are aware that ERK1/2 might not be the sole mechanism by which 
CCN3 alters the prooxidative, proinflammatory, and proapoptotic 
response in the observed aortic aneurysm phenotype of CCN3-
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aorta was isolated, and temporary ligatures were placed around proxi-
mal and distal portions of the infrarenal aorta using 6-0 suture. Por-
cine pancreatic elastase (Sigma-Aldrich, 0.4 U/ml) was used to per-
fuse the infrarenal aorta through a syringe pump for 5 minutes at a 
pressure of 100 mmHg. Echocardiography was performed to measure 
infrarenal aorta diameter 1 day prior to and 7 and 14 days after perfu-
sion by using the Vevo 770 High Resolution Imaging System (Visual 
Sonics) and the RMV-707B 30- MHz probe.
BMT. Twelve-week-old control and CCN3-deficient mice were 
lethally irradiated (11 Gy). To obtain donor BM cells, femurs and tib-
ias from both WT and CCN3-deficient mice were flushed with DPBS 
containing 2% FBS (Atlantics). A total of 2 × 106 of unfractionated BM 
cells were injected into the recipient mice through the lateral tail vein. 
Following 6 weeks of engraftment, mice were subjected to Ang II or 
saline infusion for 28 days as described above.
Apoptosis assay. Confluent primary SMCs grown in 24-well plates 
were serum deprived for 24 hours, after which cells were treated with 
vehicle or Ang II (1 μM) for 24 hours. Experiments were performed 
4 times using 4 separate SMC isolations, and for each experiment, 
treatment with Ang II or saline was carried out in triplicate. Aortic 
sections were deparaffinized and used for cell apoptosis assessment. 
For both in vitro and in vivo experiments, TUNEL staining was car-
ried out to detect apoptotic cells using In Situ Cell Death Detection 
Kit according to the manufacturer’s instructions (Roche Diagnostics 
Co.). DAPI counterstaining was performed to reveal total nuclei on 
each culture well or aorta sections using VECTASHIELD mounting 
medium (Vector Laboratories). For aortic sections, the number of 
TUNEL-positive nuclei per section was normalized to total nuclei 
using Image-Pro Plus software. Results were presented as mean ± 
SEM of the percentage of apoptotic cells.
ROS generation assay. To evaluate ROS production in primary aor-
tic SMCs, following 24 hours of Ang II treatment, cells were incubated 
with DHE (5 μM, Molecular Probes) for 30 minutes. Aortas were per-
fused with ice-cold PBS (pH 7.4) at 100 mmHg for 5 minutes at 4°C. 
The abdominal aorta was dissected and embedded in OCT (Tissue-
Tek, Miles Inc.). DHE (5 μM) was topically applied to the freshly cut 
frozen aortic sections (10 μm) and incubated at 37°C for 30 minutes. 
The presence of ROS is shown as red. DHE fluorescence images were 
acquired with an Olympus microscope using 510 nm excitation/580 
nm emission filters at the same photomultiplier tube voltage, gain, and 
offset. Images were converted to gray scale, and the integrated density 
per image area of interest was measured using NIH ImageJ (http://
imagej.nih.gov/ij/).
Cell, tissue lysis, and Western blot. Cells were treated as described 
and then harvested for total protein by RIPA buffer supplemented 
with protease inhibitor tablet (Roche). Snap-frozen aorta tissues 
were extracted using a Total Protein Extraction Kit with protease 
and phosphatase inhibitor from Millipore. Tissues were homog-
enized using a pellet pestle motor (Kimble-Kontes) according to the 
protocol in the protein extraction kit. Protein concentrations were 
determined by BCA kit (Pierce). Equal amounts of the resultant 
protein were subjected to Western blot analyses using the indicat-
ed antibodies. Membranes were reprobed with antibodies against 
β-actin (Santa Cruz Biotechnology Inc.) to confirm equal loading. 
For overexpression studies in RASMC, cells were infected with con-
trol virus (Ad-GFP) or Ad-CCN3 for 48 hours, followed by treatment 
with Ang II (1 μM) for 30 minutes, and then harvested for total pro-
this second model underscores the importance of CCN3 in main-
taining normal vascular health. The pleiotropic beneficial effects 
that CCN3 exerts to curtail AAA pathology (vascular inflamma-
tion, SMC loss, MMP elaboration, and ROS production) suggest 
that therapeutic upregulation of CCN3 could be a viable strategy 
to limit AAA growth. In support of this notion, our studies show 
that systemic increase of CCN3 levels in mice mitigates the pro-
gression of AAA. These findings thus provide proof of concept for 
nonsurgical therapies to halt aneurysm progression.
In summary, we identify matricellular protein CCN3 as a 
regulator of AAA formation. Our studies point to an important 
contribution of ERK1/2 in driving AAA pathology in the context of 
CCN3 deficiency. Moreover, our studies suggest that augmenting 
CCN3 levels may have therapeutic benefits in controlling aortic 
expansion. Future work to gain in-depth understanding of CCN3 
action may facilitate the development of a novel medical strategy 
against this vascular disease.
Methods
Mice. Ccn3-KO mice were generated as previously described (17). Erk1-
KO mice were provided by Gary Landreth (Case Western Reserve Uni-
versity) (64). WT C57BL/6 and Apoe-null mice were purchased from 
the Jackson Laboratory and maintained in our animal facility. All con-
trol and mutant mice used in this study were on a pure C57BL/6 back-
ground. Mice were housed under standard light conditions (12-hour 
light/12-hour dark cycle) and allowed ad libitum access to standard 
rodent chow and water.
Ang II infusion model. To induce AAA formation in mice, male 
mice at the age of 10 to 12 weeks were infused with Ang II as pre-
viously described (65). Alzet model 1007D, 1002, or 1004 osmotic 
minipumps (DURECT Corp.) implanted subcutaneously were used to 
deliver Ang II (1000 ng/kg/min, Sigma-Aldrich) or vehicle (normal 
saline) for 7, 14, and 28 days, depending on the experimental design 
described in Results. Mice were anesthetized with ketamine (1.5 
mg/kg) and xylazine (0.3 mg/kg), which was followed by minipump 
implantation. To relieve pain from surgery, postoperative analgesia 
was administered using intraperitoneal injection of buprenorphine 
(0.05–0.10 mg/kg administered every 8 to 12 hours) on the day of 
surgery and on postoperative days 1 to 3. To assess the severity of AAA 
formation, the methods described by Daugherty et al. were adopted 
(24). AAA is classified as follows: type I, dilated lumen in the suprare-
nal aorta with no thrombus; type II, remodeled tissue in the suprare-
nal region that frequently contains thrombus; type III, a pronounced 
bulbous form of type II that contains thrombus; and type IV, multiple 
aneurysms containing thrombus, some overlapping, in the supra-
renal area of the aorta (Supplemental Figure 19). At the completion 
of Ang II infusion, mice were perfused with normal saline followed 
by 4% paraformaldehyde at 100 mmHg for 8 minutes. The aorta was 
exposed under a dissecting microscope, periadventitial tissues were 
carefully removed from the aortic wall, and a caliper was used to mea-
sure the external diameter of suprarenal abdominal aorta. To deter-
mine AAA incidence, an aneurysm was defined by a 50% or greater 
increase in the external diameter of the suprarenal aorta in compari-
son with aortas from saline-infused WT mice.
Elastase-induced AAA model. Elastase perfusion in mice was per-
formed as previously described (20). Briefly, 8- to 12-week-old male 
mice were anesthetized with ketamine and xylazine, the infrarenal 
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used. CI-1040 was suspended in an 8:1:1 PBS:ethanol:cremophore 
solution. CCN3-deficient mice (n = 12 per group) were pretreated with 
vehicle or CI-1040 (100 mg/kg/d) by gavage for 3 days. A parallel 
experiment was conducted using JNK inhibitor (SP600125, 50 mg/
kg/d, Sigma-Aldrich) in a separate cohort of CCN3-deficient mice. 
These pretreated mice were then subjected to Ang II infusion for 28 
days, after which AAA formation was assessed. To genetically inhibit 
ERK1/2 activation, CCN3-deficient mice were crossed with Erk1-null 
mice to generate Ccn3/Erk1 compound-KO mice. The resultant mice 
were treated with saline or Ang II as described above.
ROS inhibition studies. To inhibit the formation of ROS in vivo, 
apocynin (Acros Organics) was used. Two groups of Ccn3-KO mice 
(n = 12 in each group) were included in this study. One group of 
mice received water supplemented with apocynin; the control group 
received a similar amount of water. All mice were allowed ad libitum 
access to standard rodent chow. Mice were pretreated with apocy-
nin (100 mg/kg/d) for 7 days prior to Ang II infusion, after which 
an osmotic minipump was implanted subcutaneously to deliver Ang 
II (1000 ng/kg/min) for 28 days with concurrent apocynin treat-
ment. At the end of the study, mice were sacrificed and AAA severity 
assessed as above; tissue was harvested for biochemical and mor-
phological analysis.
Histology and immunohistochemistry. These studies were per-
formed according to standard procedures. Please refer to Supplemen-
tal Methods for details. Elastin fragmentation was graded according to 
the criteria illustrated in Supplemental Figure 20. Primary antibodies 
are listed in Supplemental Table 2.
Additional experimental procedures are presented in Supplemen-
tal Methods.
Statistics. Data are expressed as mean ± SEM. To compare the inci-
dence of AAA formation between 2 groups, χ2 test and 2-tailed Fisher’s 
exact probability test were used. For comparison of the differences in 
CCN3 mRNA levels between non-AAA and AAA tissues, Mann-Whit-
ney U test was used. To compare the differences within 3 or more lev-
els within 1 variable, 1-way ANOVA was used. For comparison of the 
effects of 2 variables, 2-way ANOVA followed by Bonferroni’s post-
hoc correction was used. P ≤ 0.05 was considered significant.
Study approval. For human samples used in RNA analysis, AAA tis-
sue was collected from patients undergoing AAA repair, as previously 
described (19). Control abdominal aortic specimens were matched to 
cases using sex, age, and ethnicity, as described (19). All aortic speci-
mens were obtained by protocols approved by the Institutional Review 
Board of Wayne State University. All tissues were collected in RNAlater 
(Ambion), followed by RNA extraction. A separate set of aortic tissues 
used in immunohistochemistry studies was obtained by protocols 
approved by the Human Investigation Review Committee at Brigham 
and Women’s Hospital. Samples were immediately immersed in 
saline, embedded in OCT, and stored at –80°C (68). These sections 
were used in evaluating CCN3 expression in human aorta samples 
from non-AAA control and AAA patients. All animal protocols were 
approved by the Institutional Animal Care and Use Committee at 
Case Western Reserve University, which is certified by the American 
Association of Accreditation for Laboratory Animal Care.
Author contributions
CZ and ZL conceived and designed the research studies. CZ, 
DVDV, HS, RZ, YQ, and DAP performed experiments and/or 
tein. The resultant protein was subjected to Western blot analyses 
using the indicated antibodies. CCN3 proteins in the conditioned 
medium were concentrated using heparin sepharose beads (Amer-
sham) as described by Chevalier et al. (66). Briefly, supernatants 
were incubated overnight with heparin and then washed 4 times in 
PBS containing protease inhibitors. Bound CCN3 was dissociated 
using 2-mercaptoethanol in Laemmli buffer, boiled for 10 minutes, 
and then centrifuged. The supernatant was collected for Western 
blot assay of the free protein. Heparin sepharose–concentrated 
samples and cellular extracts were subjected to Western blot analy-
ses using CCN3 (K19M) antibody (66). Other primary antibodies 
are listed in Supplemental Table 1.
MMP activity measurement in tissue lysate and in situ. MMP2 and 
MMP9 activities in abdominal aorta tissue homogenate were deter-
mined by zymography. Equal amounts of nonreduced aorta lysate 
were run on Novex 10% Zymogram (gelatin) Protein Gels (Invitro-
gen). After electrophoresis, gels were renatured with Novex Zymo-
gram Renaturing Buffer for 30 minutes at room temperature. The gels 
were then put in developing buffer and incubated overnight at 37°C. 
Finally SimplyBlue Safestain (Invitrogen) was applied to visualize 
protease activity. In situ MMP zymography was performed on freshly 
cut OCT-embedded aorta sections. Fluorescein-conjugated gela-
tin substrate DQ gelatin (Invitrogen) was prepared according to the 
manufacturer’s instructions. The substrates were then applied to sec-
tions and allowed to incubate at 37°C for 24 hours, after which green 
fluorescence was examined using a fluorescent microscope. Negative 
controls were performed on parallel sections in the presence of 5 mM 
EDTA. Pictures were taken and fluorescence intensity calculated with 
ImageJ (67). The results were expressed as percentage of fluorescence 
area over each cross section.
Lentivirus- and adenovirus-mediated overexpression. C57BL/6 
male mice (8 to 10 weeks old) underwent elastase perfusion surgery 
as described above. One day prior to surgery, mice underwent injec-
tion of lentivirus that harbored mouse Ccn3 cDNA (lentivirus gener-
ated by Welgen) or control virus. To achieve sustained expression of 
CCN3 in mice, control or Ccn3 lentivirus (1.0 × 108 IFU) was injected 
into elastase-treated C57BL/6 mice via tail vein. The infrarenal aorta 
diameter was measured at –1, 7, and 14 days after elastase perfusion 
by echocardiography. Fourteen days following elastase perfusion, 
mice were sacrificed and external infrarenal aorta diameters were 
measured. The mice were perfused with ice-cold PBS, and the infra-
renal aorta was segmented in half and embedded in paraffin and 
OCT medium, respectively. Paraffin sections were used for H&E and 
elastin staining as well as immunohistochemical analysis. Freshly 
cut OCT sections were used for ROS generation assessment by DHE 
staining. Thoracic portions of aortas were snap-frozen for total pro-
tein extraction and assessed for CCN3 protein expression. To assess 
the effect of perivascular Ccn3 overexpression in the Apoe–/– mouse 
AAA model, control or Ccn3 adenovirus (1 × 1010 PFU, generated by 
Welgen) was injected directly into the adventitial space of suprarenal 
abdominal aorta, which was followed by Ang II pump implantation 
on the same day. The suprarenal aorta diameter was measured at –14 
days after Ang II infusion.
In vivo ERK1/2 inhibition. Two approaches were undertaken to 
address the importance of Erk1/2 activation in AAA formation in 
CCN3-deficient aorta. To pharmacologically inhibit ERK1/2 activa-
tion, CI-1040 (Selleck Chemicals), a well-studied MEK inhibitor, was 
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